WO2007072147A3 - Composition for diagnosing and treating circulatory system diseases - Google Patents

Composition for diagnosing and treating circulatory system diseases Download PDF

Info

Publication number
WO2007072147A3
WO2007072147A3 PCT/IB2006/003630 IB2006003630W WO2007072147A3 WO 2007072147 A3 WO2007072147 A3 WO 2007072147A3 IB 2006003630 W IB2006003630 W IB 2006003630W WO 2007072147 A3 WO2007072147 A3 WO 2007072147A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
diagnosing
circulatory system
system diseases
treating
Prior art date
Application number
PCT/IB2006/003630
Other languages
French (fr)
Other versions
WO2007072147A2 (en
Inventor
Pieter Theo Ernst
Original Assignee
Ernst Johanna Catarina
Ernst Pieter Benjamin
Ernst Hugo Alexander
Ernst Maxwell Theodore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005907104A external-priority patent/AU2005907104A0/en
Application filed by Ernst Johanna Catarina, Ernst Pieter Benjamin, Ernst Hugo Alexander, Ernst Maxwell Theodore filed Critical Ernst Johanna Catarina
Publication of WO2007072147A2 publication Critical patent/WO2007072147A2/en
Publication of WO2007072147A3 publication Critical patent/WO2007072147A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

This invention relates to a composition for diagnosing and for treating circulatory system diseases by administering a composition which comprises a first solution which contains magnesium sulphate, heparin sodium, sodium bicarbonate in electro-potentiated water and a second solution which contains ascorbic acid, lignocaine, vitamin B12, thiamin, riboflavin, nicotinamide, pyridoxine, D-pantothenol in electro-potentiated water. The first and second solutions are mixed prior to administration by injection into a mammal suffering from a vascular occlusion disorder. The invention also extends to a method of treating vascular disorders and to a method of diagnosing circulatory system diseases both using the composition.
PCT/IB2006/003630 2005-12-19 2006-12-15 Composition for diagnosing and treating circulatory system diseases WO2007072147A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005907104A AU2005907104A0 (en) 2005-12-19 Circulatory System Disease Diagnosis and Treatment
AU2005907104 2005-12-19

Publications (2)

Publication Number Publication Date
WO2007072147A2 WO2007072147A2 (en) 2007-06-28
WO2007072147A3 true WO2007072147A3 (en) 2007-11-01

Family

ID=38121999

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003630 WO2007072147A2 (en) 2005-12-19 2006-12-15 Composition for diagnosing and treating circulatory system diseases

Country Status (2)

Country Link
WO (1) WO2007072147A2 (en)
ZA (1) ZA200610628B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
CN104997803B (en) 2010-07-22 2019-07-09 雷文制药有限公司 Comprising the treatment using magnetic dipole stabilizing solutions or improves disease and enhance the method and composition of performance
CN110292639A (en) * 2011-01-06 2019-10-01 C·洛维尔·帕森斯 The method of composition of the manufacture comprising local anesthetic, heparan and buffer
CN115245143A (en) * 2022-07-06 2022-10-28 上海市中西医结合医院 Construction method of artery occlusive disease animal model

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035943A2 (en) * 1999-11-15 2001-05-25 Gangal Hanamaraddi T Dextrose and insulin fluid formulation for intravenous infusion
US6284293B1 (en) * 2000-04-12 2001-09-04 Jeffery J. Crandall Method for generating oxygenated water
WO2002045705A2 (en) * 2000-12-08 2002-06-13 Pieter Theo Ernst Regenaration of blood vessels
WO2005039602A1 (en) * 2003-10-24 2005-05-06 Miz Co., Ltd. Pharmacologically functional water and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035943A2 (en) * 1999-11-15 2001-05-25 Gangal Hanamaraddi T Dextrose and insulin fluid formulation for intravenous infusion
US6284293B1 (en) * 2000-04-12 2001-09-04 Jeffery J. Crandall Method for generating oxygenated water
WO2002045705A2 (en) * 2000-12-08 2002-06-13 Pieter Theo Ernst Regenaration of blood vessels
WO2005039602A1 (en) * 2003-10-24 2005-05-06 Miz Co., Ltd. Pharmacologically functional water and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGARWAL P ET AL: "Intravenous infusion for the treatment of diabetic and ischaemic non-healing pedal ulcers.", JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY : JEADV MAR 2005, vol. 19, no. 2, March 2005 (2005-03-01), pages 158 - 162, XP009087030, ISSN: 0926-9959 *
DATABASE WPI Week 200535, Derwent World Patents Index; AN 2005-346614, XP002443501 *

Also Published As

Publication number Publication date
ZA200610628B (en) 2008-06-25
WO2007072147A2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
Murray et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
Abe et al. Comparison of sustained hemodiafiltration with continuous venovenous hemodiafiltration for the treatment of critically ill patients with acute kidney injury
WO2005009398A3 (en) Tetracyclic benzamide derivatives and methods of use thereof
WO2008062440A3 (en) Programmable buoyant delivery technology
WO2003053219A3 (en) Methods for slowing senescence and treating and preventing diseases associated with senescence
WO2008150486A3 (en) 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2006026555A3 (en) Neuroprotective effect of solubilized udca in focal ischemic model
WO2004010894A3 (en) Ophthalmologic irrigation solutions and method
WO2004045679A1 (en) Peritoneal dialysis method
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
MX2009008166A (en) Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts.
EP1968561B8 (en) Treatment of diabetic nephropathy
WO2007072147A3 (en) Composition for diagnosing and treating circulatory system diseases
EA201100756A1 (en) METHOD OF TREATMENT OR PREVENTION OF THROMBOSIS BY USING DAGIGATRAN ETHESYLATE OR ITS SALT WITH AN IMPROVED SAFETY PROFILE AS COMPARED TO STANDARD TREATMENT WARFARIN
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2001082949A3 (en) Method of reducing side effects of chemotherapy in cancer patients
WO2007070637A3 (en) Method of treating open wounds using hypochlorous acid
Harenberg et al. Anticoagulation in patients with impaired renal function and with haemodialysis
DE602006009641D1 (en) COMPLEMENTARY COMPOSITIONS FOR REDUCING BLOOD SUGAR MIRRORS AND TREATING DIABETES
NO20051390L (en) Procedure for treating patients with massive blood loss
Ogawa et al. Urgent statement on antithrombotic therapy of atrial fibrillation
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06831722

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06831722

Country of ref document: EP

Kind code of ref document: A2